Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Cassava Slumps on Report SEC Probing Developer of Alzheimer’s Drug

Published 17/11/2021, 15:12
Updated 17/11/2021, 15:12
© Reuters.

© Reuters.

By Dhirendra Tripathi

Investing.com – Cassava stock (NASDAQ:SAVA) plunged 20% Wednesday on reports the Securities and Exchange Commission is investigating claims that the company manipulated research results of simufilam, its experimental drug for Alzheimer’s.

The company disclosed Monday in an SEC filing it is cooperating with government investigations. It said an investigation isn’t a sign any wrongdoing occurred. It did not the name any agency probing it.

The National Institutes of Health, which awarded $20 million in grants to Cassava and its academic collaborators since 2015 for drug development, is also examining the claims, The Wall Street Journal said, quoting the company’s chief executive officer.

The accusations surfaced in August when two physicians petitioned the Food and Drug Administration to order suspension of Cassava’s clinical trials.

Disputing the validity of Cassava’s clinical biomarker data and the integrity of Western Blot Analysis, the petition’s authors said they doubted the company’s research claiming it included images that appeared manipulated.

Cassava said the biomarker data of Alzheimer’s patients was generated by Quanterix (NASDAQ:QTRX), an independent company, and presented at the recent Alzheimer’s Association International Conference.

The company said Western Blot Analysis is foundational to the biotechnology industry and is a standard lab technique used worldwide to detect a protein of interest.

Cassava’s proposed drug for Alzheimer’s aims to restore a protein, filamin A, that its scientists say is misshaped in the blood of patients suffering from the fatal illness.

Earlier this month, the Journal of Neuroscience said it had found no evidence of data manipulation in an article it published in July 2012 describing a new approach to treating Alzheimer's disease.

Cassava’s lead drug candidate for treating Alzheimer’s is currently in a phase-3 clinical program.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.